Shares of contract research organization (CRO) companies are leading gains in Hong Kong trading, driven by a wave of better-than-expected earnings from global CXO industry leaders that underscores a confirmed recovery in worldwide demand.

As of the latest trading update, Asymchem (06821) surged 8.46% to HKD 120.50, while Genscript Bio (01548) advanced 4.41% to HKD 34.06. Tigermed (03347) climbed 4.27% to HKD 39.60, and WuXi Bio (02269) gained 3.29% to HKD 50.20.

On the news front, major overseas CXO players, including IQVIA, Medpace, Lonza, and Samsung Biologics, have released their latest financials, revealing a robust turnaround in order backlogs and multiple upward revisions to their full-year guidance. IQVIA posted second-quarter revenue of USD 4.368 billion, up 9% year-over-year, with net new bookings in its R&D solutions segment rising 19% annually. The company's book-to-bill ratio reached 1.22x, and its backlog hit a record USD 34.2 billion. Medpace reported second-quarter new bookings of USD 796 million, a 28% increase, with its book-to-bill ratio recovering from 0.88x to 1.13x. Lonza raised its full-year margin guidance to a range of 33% to 34%, while Samsung Biologics projects full-year revenue growth could reach the upper end of its 15% to 20% target.

Analysts at Xiangcai Securities noted that the recent standout performance across the CRO sector reflects a broader global trend of improving industry fundamentals, supported by a rebound in healthcare financing. Chinese CRO companies, benefiting from an engineering talent dividend, are well-positioned to capitalize on this industry upswing, and the sustainability of this momentum is expected to be strong as the global sector continues to improve.